Tudor Investment Corp ET AL Sells 193,399 Shares of Accuray Incorporated (NASDAQ:ARAY)

Tudor Investment Corp ET AL trimmed its holdings in Accuray Incorporated (NASDAQ:ARAY - Free Report) by 64.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 108,362 shares of the medical equipment provider's stock after selling 193,399 shares during the period. Tudor Investment Corp ET AL owned 0.11% of Accuray worth $215,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Barclays PLC raised its stake in Accuray by 97.9% during the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider's stock valued at $380,000 after purchasing an additional 104,310 shares during the last quarter. Geode Capital Management LLC raised its stake in Accuray by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider's stock valued at $4,329,000 after purchasing an additional 6,758 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Accuray by 28.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 212,330 shares of the medical equipment provider's stock valued at $420,000 after purchasing an additional 47,331 shares during the last quarter. Jane Street Group LLC raised its stake in Accuray by 26.1% during the 3rd quarter. Jane Street Group LLC now owns 161,653 shares of the medical equipment provider's stock valued at $291,000 after purchasing an additional 33,417 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Accuray by 6.8% during the 4th quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider's stock valued at $5,900,000 after purchasing an additional 189,414 shares during the last quarter. 64.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Accuray from a "hold" rating to a "buy" rating in a research note on Tuesday.

Accuray Price Performance

Shares of ARAY stock traded up $0.04 during mid-day trading on Friday, reaching $1.63. The company's stock had a trading volume of 124,405 shares, compared to its average volume of 710,903. Accuray Incorporated has a 1-year low of $1.28 and a 1-year high of $2.95. The company has a market cap of $167.40 million, a P/E ratio of -32.50 and a beta of 1.30. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. The firm's 50-day moving average is $1.63 and its two-hundred day moving average is $1.91.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The company had revenue of $113.24 million during the quarter, compared to analysts' expectations of $101.53 million. On average, research analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.